JARVISDHL Screening Tools

Last updated: November 22, 2022
Sponsor: National Heart Centre Singapore
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Heart Disease

Atherosclerosis

Thrombosis

Treatment

N/A

Clinical Study ID

NCT05626517
R1869/111/2021
  • Ages 21-99
  • All Genders

Study Summary

The main purpose of this study is to pioneer an easy risk stratification tools, which is developed using novel artificial intelligence (AI) algorithms, that will be able to detect common and fatal heart diseases easily simply through a picture of the back of the eye, the retina. The retinal images will be analysed using a computer application with the risk stratification tool to predict health outcome of individual. The study also aims to correlate between clinical characteristics, lifestyle (eg. exercise, sleep, erectile dysfunction) and diet to retinal and coronary vasculature and clinical outcomes.

Eligibility Criteria

Inclusion

Inclusion Criteria for NHCS:

  1. 21 years of age or older

  2. Sufficient language skills in English or Chinese

  3. Provided informed consent

  4. Completed CTCA or CT CAC in the past 6 months.

Inclusion Criteria for SERI:

  1. 21 years of age or older

  2. Sufficient language skills in English or Chinese

  3. Provided informed consent

  4. Patient diagnosed with Diabetes for more than or equal to 10 years.

Exclusion Criteria for NHCS:

  1. Patients whose informed consent was not obtained.

  2. Age <21 years old

  3. Patients with cardiac event (acute myocardial infarction, Stroke, heart failure, angina requiring hospitalization) and/or coronary revascularization (percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG) prior to CTCA

Exclusion Criteria in SERI:-

  1. Patient whose informed consent was not obtained.

  2. Age <21 years old

  3. Patients with cardiac event (acute myocardial infarction, Stroke, heart failure, angina requiring hospitalization) and/or coronary revascularization (percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG) prior to CTCA

Study Design

Total Participants: 2000
Study Start date:
January 30, 2023
Estimated Completion Date:
June 30, 2027

Study Description

Cardiovascular disease (CVD) is ranked 1st for mortality rate globally. In 2016, approximately 17.9 million people died from CVDs, representing 31% of all global deaths.

Retinal vasculature has been characterised as the 'window' to the body's circulatory system and been correlated with several diseases that perturbate systemic micro- and macro-vasculature such as hypertension, stroke and chronic kidney disease.

As microvascular changes often precede macrovascular changes, retinal imaging has the capability to be an easily available, non-invasive biomarker to screen for multiple vascular pathologies. A deep learning system (DLS) is a novel,state-of-art artificial intelligence (AI) technology that has achieved robust diagnostic performance for medical imaging analysis. The integration of deep learning (DL) into retinal image evaluation has accelerated its potential further. Its examination of fundus photographs has demonstrated abilities to detect several signs that are undetected by the human eye. With recent correlations being established between CAD and retinal vasculature aberrancies such as reduced calibres and fractal dimensions, there is a clear niche for AI to predict cardiac diseases with the use of retinal fundus photographs.

Connect with a study center

  • National Heart Centre Singapore

    Singapore, 169609
    Singapore

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.